• BOP Reagent for Peptide and Prodrug Workflows

  2026-09-05

  BOP reagent combines rapid carboxyl group activation with practical routes to amide bond formation and phenyl ester preparation. This guide connects routine peptide chemistry to the upstream synthesis and assay planning of ROS-responsive triterpene prodrug systems, while clearly separating demonstrated evidence from optimization starting points.

• Gly-Gly-Phe-Gly (GGFG) in Assay Design

  2026-09-04

  Gly-Gly-Phe-Gly (GGFG) is more than a flexible peptide spacer: it can be treated as a controlled design variable in bioconjugation and translational assay development. This article connects GGFG workflow decisions with stress-response pharmacology while clearly separating product facts, published evidence, and experimental hypotheses.

• Pancreatic Ductal Organoids: Small-Molecule Advances

  2026-09-04

  Liao and colleagues developed a small-molecule-based culture strategy that improves the initiation and long-term expansion of pancreatic ductal organoids while retaining ductal and acinar heterogeneity. The resulting platform offers a more efficient model for pancreatic disease studies, cellular plasticity research, and high-throughput drug screening.

• Ceruletide: Designing Mechanistic Pancreatitis Assays

  2026-09-03

  Ceruletide, also known as Caerulein, is more than a secretagogue: it is a controllable physiological perturbation for linking pancreatic injury to fibrosis mechanisms. This guide shows how the ORM2–ZG16 study can inform assay design, controls, readouts, and model interpretation.

• Gly-Gly-Phe-Gly (GGFG) in Reliable Assays

  2026-09-03

  This scenario-driven guide explains how Gly-Gly-Phe-Gly (GGFG), SKU C8670, can improve control of peptide-conjugate workflows without being mistaken for a direct viability reagent. It connects linker identity, storage, assay controls, interpretation, and vendor selection to practical needs in drug conjugation research and antibody-drug conjugate development.

• CA-074 Me: Reliable Lysosomal Assays

  2026-09-02

  This scenario-driven guide explains how CA-074 Me (Cathepsin B inhibitor), SKU A8239, can improve interpretation of viability, apoptosis, and lysosomal membrane permeabilization assays. It covers formulation, controls, imaging parameters, cathepsin selectivity, and practical product-selection criteria.

• Moxidectin–Polyene Synergy in Oral Candidiasis

  2026-09-02

  A 2024 study found that Moxidectin enhances amphotericin B and nystatin activity against Candida albicans by increasing fungal ergosterol biosynthesis and polyene binding. The work combines isolate testing, transcriptomics, ergosterol-pathway mutants, and a mouse oral candidiasis model to support Moxidectin as a preclinical polyene potentiator rather than a stand-alone antifungal.

• CDK4 Phosphorylation of 4E-BP1 Revealed by PhAXA

  2026-09-01

  Mitchell, Menon, and Garner developed PhAXA, a chemoproteomic strategy for identifying kinase–substrate interactions with phosphorylation-site specificity. The study linked CDK4 to 4E-BP1 phosphorylation, helping explain persistent cap-dependent translation and c-Myc expression during mTORC1 inhibition in breast cancer cell models.

• FLAG tag Peptide: Assay Design for Kinesin

  2026-09-01

  Learn how the FLAG tag Peptide (DYKDDDDK) can be used to build cleaner recombinant protein purification and detection workflows. This guide connects epitope-tag chemistry with assay design principles from recent kinesin activation research.

• Boc-D-FMK Workflows for Apoptosis Research

  2026-08-31

  Boc-D-FMK gives researchers a practical way to test whether caspase activation drives cell death, endothelial inflammation, or hepatocyte injury. This workflow-focused guide combines pathway controls, solubility safeguards, and a reference-informed fibrosis assay strategy for more interpretable results.

• Polymyxin B: From Membrane Damage to Translation

  2026-08-31

  Polymyxin B sulfate is more than a rescue antibiotic model. Its membrane-disruptive activity, immune-signaling effects, and potential to reshape microbiome-aware experimental design make it a valuable reference perturbation for translational infection and immunity research.

• JHU-083 for Glutaminase Pathway Research

  2026-08-30

  JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway studies in cerebral CD11b cells and experimental cerebral malaria research. This workflow-focused guide shows how to connect glutamate measurements with oxidative-stress assays while avoiding unsupported conclusions in hepatic models.

• Belinostat (PXD101) Workflow for HDAC Research

  2026-08-29

  Build reproducible Belinostat assays around histone acetylation, cell-cycle arrest, and cancer-cell viability rather than relying on a single endpoint. This workflow connects bladder and prostate model benchmarks with a hypothesis-driven extension into acetylation-sensitive spliceosome and DNA-repair studies.

• Anlotinib hydrochloride: Angiogenesis Assay Guide

  2026-08-28

  Anlotinib hydrochloride connects VEGFR2, PDGFRβ, and FGFR1 pharmacology with measurable endothelial phenotypes, making it useful for mechanism-led angiogenesis studies. This guide translates its reported potency into practical migration, tube-formation, signaling, and translational cancer research workflows.

• PYR-41: Decoding E1 Control in Translational Biology

  2026-08-28

  A mechanistic and strategic guide to using PYR-41 to interrogate ubiquitination, NF-κB signaling, antiviral immunity, apoptosis, and inflammation without confusing pathway perturbation with therapeutic validation.

7832 records 1/523 page Next 12345 下5页 Last page